Advocacy at a Glance STEVEN GROSSMAN 8/19/22 Advocacy at a Glance STEVEN GROSSMAN 8/19/22 FY23 Appropriations Continuing Resolution; User Fee Status Unchanged Read More Analysis and Commentary STEVEN GROSSMAN 8/19/22 Analysis and Commentary STEVEN GROSSMAN 8/19/22 FAQ about FDA Funding for Fiscal Year 2023—Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 8/12/22 Analysis and Commentary STEVEN GROSSMAN 8/12/22 FAQ about FDA Funding for Fiscal Year 2023 Read More Advocacy at a Glance STEVEN GROSSMAN 8/12/22 Advocacy at a Glance STEVEN GROSSMAN 8/12/22 August Recess; User Fees Uncertain; Transcript of Dr. Woodcock Webinar Read More Analysis and Commentary STEVEN GROSSMAN 8/5/22 Analysis and Commentary STEVEN GROSSMAN 8/5/22 Summary of Alliance's Webinar with Dr. Janet Woodcock on FDA Data and Technology Modernization Read More Advocacy at a Glance STEVEN GROSSMAN 8/5/22 Advocacy at a Glance STEVEN GROSSMAN 8/5/22 FY23 Appropriations; User fees; Dr. Woodcock on User Fees and Future of FDA Knowledge Management Read More Analysis and Commentary STEVEN GROSSMAN 7/29/22 Analysis and Commentary STEVEN GROSSMAN 7/29/22 Details on the Draft Senate FY 23 Funding Bill for FDA Read More Advocacy at a Glance STEVEN GROSSMAN 7/29/22 Advocacy at a Glance STEVEN GROSSMAN 7/29/22 FY 23 Appropriations Update; User-fee Lay-off Risk; Woodcock Webinar Announcement Read More Analysis and Commentary STEVEN GROSSMAN 7/22/22 Analysis and Commentary STEVEN GROSSMAN 7/22/22 Untangling FDA’s FY 23 Funding: Appropriations and User Fees Hit Peak Uncertainty Read More Advocacy at a Glance STEVEN GROSSMAN 7/22/22 Advocacy at a Glance STEVEN GROSSMAN 7/22/22 Woodcock Webinar; FY23 Appropriations Minibus; and FDA Food Safety Programs face Congress and Independent Review Read More Analysis and Commentary STEVEN GROSSMAN 7/15/22 Analysis and Commentary STEVEN GROSSMAN 7/15/22 What Dr. Califf Told Us About His Plans for FDA Read More Advocacy at a Glance STEVEN GROSSMAN 7/15/22 Advocacy at a Glance STEVEN GROSSMAN 7/15/22 Ag/FDA FY23 Approps Update, User Fee Reauthorization Uncertainty, and Dr. Woodcock Webinar Announcement Read More Analysis and Commentary STEVEN GROSSMAN 7/8/22 Analysis and Commentary STEVEN GROSSMAN 7/8/22 Some Likely Questions at the Alliance Webinar with the Commissioner; Feedback on Alliance Senate Visits Read More Advocacy at a Glance STEVEN GROSSMAN 7/8/22 Advocacy at a Glance STEVEN GROSSMAN 7/8/22 House and Senate Calendar Updates; Understaffed FDA Offices; Inspections Updates Read More Analysis and Commentary Lisa Ellington 6/24/22 Analysis and Commentary Lisa Ellington 6/24/22 Resisting the Impulse to Cut FDA Funding During Times of Controversy Read More Advocacy at a Glance Lisa Ellington 6/24/22 Advocacy at a Glance Lisa Ellington 6/24/22 Commissioner Califf to Address Alliance for a Stronger FDA: July 12 from 1:30 to 2:30. Read More Analysis and Commentary Lisa Ellington 6/17/22 Analysis and Commentary Lisa Ellington 6/17/22 Messaging for the Alliance’s Upcoming Senate Hill Meetings Read More Advocacy at a Glance Lisa Ellington 6/17/22 Advocacy at a Glance Lisa Ellington 6/17/22 House Subcommittee Includes 10% Increase For FDA Read More Analysis and Commentary Lisa Ellington 6/10/22 Analysis and Commentary Lisa Ellington 6/10/22 Appropriations Mark-ups; the Deeming Resolution; The Possible Return of Hurry Up and Wait Read More Advocacy at a Glance Lisa Ellington 6/10/22 Advocacy at a Glance Lisa Ellington 6/10/22 House Appropriators Schedule FY 23 Mark-ups Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 8/19/22 Advocacy at a Glance STEVEN GROSSMAN 8/19/22 FY23 Appropriations Continuing Resolution; User Fee Status Unchanged Read More
Analysis and Commentary STEVEN GROSSMAN 8/19/22 Analysis and Commentary STEVEN GROSSMAN 8/19/22 FAQ about FDA Funding for Fiscal Year 2023—Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 8/12/22 Analysis and Commentary STEVEN GROSSMAN 8/12/22 FAQ about FDA Funding for Fiscal Year 2023 Read More
Advocacy at a Glance STEVEN GROSSMAN 8/12/22 Advocacy at a Glance STEVEN GROSSMAN 8/12/22 August Recess; User Fees Uncertain; Transcript of Dr. Woodcock Webinar Read More
Analysis and Commentary STEVEN GROSSMAN 8/5/22 Analysis and Commentary STEVEN GROSSMAN 8/5/22 Summary of Alliance's Webinar with Dr. Janet Woodcock on FDA Data and Technology Modernization Read More
Advocacy at a Glance STEVEN GROSSMAN 8/5/22 Advocacy at a Glance STEVEN GROSSMAN 8/5/22 FY23 Appropriations; User fees; Dr. Woodcock on User Fees and Future of FDA Knowledge Management Read More
Analysis and Commentary STEVEN GROSSMAN 7/29/22 Analysis and Commentary STEVEN GROSSMAN 7/29/22 Details on the Draft Senate FY 23 Funding Bill for FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 7/29/22 Advocacy at a Glance STEVEN GROSSMAN 7/29/22 FY 23 Appropriations Update; User-fee Lay-off Risk; Woodcock Webinar Announcement Read More
Analysis and Commentary STEVEN GROSSMAN 7/22/22 Analysis and Commentary STEVEN GROSSMAN 7/22/22 Untangling FDA’s FY 23 Funding: Appropriations and User Fees Hit Peak Uncertainty Read More
Advocacy at a Glance STEVEN GROSSMAN 7/22/22 Advocacy at a Glance STEVEN GROSSMAN 7/22/22 Woodcock Webinar; FY23 Appropriations Minibus; and FDA Food Safety Programs face Congress and Independent Review Read More
Analysis and Commentary STEVEN GROSSMAN 7/15/22 Analysis and Commentary STEVEN GROSSMAN 7/15/22 What Dr. Califf Told Us About His Plans for FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 7/15/22 Advocacy at a Glance STEVEN GROSSMAN 7/15/22 Ag/FDA FY23 Approps Update, User Fee Reauthorization Uncertainty, and Dr. Woodcock Webinar Announcement Read More
Analysis and Commentary STEVEN GROSSMAN 7/8/22 Analysis and Commentary STEVEN GROSSMAN 7/8/22 Some Likely Questions at the Alliance Webinar with the Commissioner; Feedback on Alliance Senate Visits Read More
Advocacy at a Glance STEVEN GROSSMAN 7/8/22 Advocacy at a Glance STEVEN GROSSMAN 7/8/22 House and Senate Calendar Updates; Understaffed FDA Offices; Inspections Updates Read More
Analysis and Commentary Lisa Ellington 6/24/22 Analysis and Commentary Lisa Ellington 6/24/22 Resisting the Impulse to Cut FDA Funding During Times of Controversy Read More
Advocacy at a Glance Lisa Ellington 6/24/22 Advocacy at a Glance Lisa Ellington 6/24/22 Commissioner Califf to Address Alliance for a Stronger FDA: July 12 from 1:30 to 2:30. Read More
Analysis and Commentary Lisa Ellington 6/17/22 Analysis and Commentary Lisa Ellington 6/17/22 Messaging for the Alliance’s Upcoming Senate Hill Meetings Read More
Advocacy at a Glance Lisa Ellington 6/17/22 Advocacy at a Glance Lisa Ellington 6/17/22 House Subcommittee Includes 10% Increase For FDA Read More
Analysis and Commentary Lisa Ellington 6/10/22 Analysis and Commentary Lisa Ellington 6/10/22 Appropriations Mark-ups; the Deeming Resolution; The Possible Return of Hurry Up and Wait Read More
Advocacy at a Glance Lisa Ellington 6/10/22 Advocacy at a Glance Lisa Ellington 6/10/22 House Appropriators Schedule FY 23 Mark-ups Read More
